Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide: an Interventional Prospective Study

Trial Profile

Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide: an Interventional Prospective Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Diabetic macular oedema
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 19 May 2015 Planned initiation date changed from 1 Dec 2014 to 1 Aug 2015, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top